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Abstract  
Background Parenteral iron is integral in the treatment of anaemia of chronic kidney 
disease (CKD) patients on haemodialysis (HD). However, increased liver iron concentration 
(LIC) can result from such treatment and this correlates poorly with serum ferritin or 
transferrin saturation values. It is unclear whether increased cardiac iron concentration 
also occurs in this setting. We aimed to evaluate the relationship of intravenous iron 
supplementation to hepatic and cardiac iron deposition in chronic HD subjects. 
Methods A cohort of 10 patients on chronic HD for at least 1 year underwent MRI-based 
quantitation of hepatic and cardiac iron content to evaluate the relationship between 
intravenous iron supplements and hepatic and cardiac iron deposition. The results were 
compared against the cumulative parenteral iron dose and serum iron markers. 
Results The median age was 61 years (95% confidence interval (CI) 50 - 71), HD time 2.5 
years (95%CI 2.0-5.3) and cumulative iron dose 4300mg (95%CI 2110-9045). Hepatic iron 
concentration was elevated in 8 of 10 subjects (median 46mmol/kg, range 31-76). Cardiac 
iron levels were within the reference range in all subjects. There was poor correlation 
between conventional haematinic values and either LIC or cardiac iron levels. None of the 
study subjects exhibited elevated cardiac iron concentration.   
Conclusion Whilst HD patients receiving standard parenteral iron therapy have elevated 
LICs, this is not associated with cardiac iron deposition. Transferrin saturation and serum 
ferritin levels are poor markers of either liver or cardiac iron deposition in HD subjects. 
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Introduction 
The growing number of patients with diabetes mellitus and hypertension has been 
accompanied by an increased incidence of chronic kidney disease (CKD)1, including end-
stage kidney disease (ESKD). The 2015 ANZDATA report identified 12,091 ESKD patients 
treated with peritoneal dialysis or haemodialysis (HD) in Australia2. CKD is an 
inflammatory condition associated with high levels of circulating IL-6. This stimulates 
hepcidin production disrupting enteric iron absorption and tissue iron release3-5. This 
causes both absolute and functional iron deficiency and is one of the principle causes of 
anaemia in this population. Because anaemia is associated with increased mortality and 
morbidity 6-8 HD patients are routinely prescribed erythropoetic stimulating agents (ESA) 
and parenteral iron to increase haemoglobin levels9, 10. The KHA-CARI (Kidney Health 
Australia - Caring for Australians with Renal Impairment) guidelines on the use of iron in 
CKD patients recommend adjustments on iron dosage based on serum ferritin and 
transferrin saturation (TSAT) values 10. This approach is inherently inaccurate, as these 
parameters are influenced by the systemic inflammation associated with CKD11, 12. The 
uncertainty is reflected in the varied recommendations of national-guidelines worldwide. 
Japanese recommendations in particular are more conservative than their Australian 
counterparts13, 14. Excess reabsorption or administration of iron leads to toxic 
accumulation, as there is no physiological mechanism for excretion. Surplus iron 
accumulates within metabolically active tissues, where it is transiently stored as ferritin. 
If the cell’s storage capability is overwhelmed, free ferric ions may accumulate in the 
cytosol causing oxidative stress and eventually cell dysfunction or death 15.  
Innovative magnetic resonance imaging (MRI) techniques such as FerriScan and T2*/R2* 
cardiac MRI provide a well-validated, non-invasive means to measure hepatic and cardiac 
iron deposition that is independent of systemic inflammatory states16, 17. Using R2* 
Ferriscan to measure liver iron concentrations (LIC) Ferrari et al demonstrated elevated 
LIC in some HD patients receiving standard iron dosages 12 and these findings were 
confirmed by Rostoker et al.18. Although ESKD is associated with dysfunction of many 
organs, the liver is rarely a cause of significant morbidity in this cohort. The leading cause 
of death in HD patients is sudden cardiac death (SCD)19. In these patients coronary artery 
disease and heart failure are often not the underlying cause of SCD and other factors such 
as electrolyte shift or vascular calcification are presumed to play a greater in SCD19. An 
alternative explanation for the high incidence of SCD in HD patients could be cardiac iron 
overload. Whether the observed increased LIC in dialysis patients 12 is accompanied by 
evidence of increased cardiac iron deposition has not been extensively investigated. Only 
one recent study reported on a lack of evidence for cardiac iron overload despite 
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moderate liver iron overload both measured as T2* MRI in long-term HD patients20. 
However, there is poor agreement between T2*-LIC with R2-LIC (Ferriscan)21, the latter 
being the method used in previous studies that assessed liver iron overload in CKD patient 
12, 18. Therefore this pilot study was designed to evaluate the relationship of intravenous 
iron supplementation to hepatic measured by R2-Ferriscan and cardiac iron deposition 
measured by cardiac T2* in chronic HD patients. 
 
Methods 
The study included patients on chronic maintenance HD that satisfied the following 
inclusion criteria: (1) maintenance HD for at least 12 months, (2) standard parenteral iron 
therapy for at least 12 months, (3) full history of all parenteral iron infusions and blood 
transfusions since commencing HD, (3) no contraindications to MR imaging, (4) alcohol 
consumption of less than two standard drinks per day, (5) absence of liver disease, active 
malignancy, pregnancy or other confounding illnesses. Exclusion criteria were (1) absolute 
or functional iron deficiency (ferritin <100µg/L and/or TSAT <20%), (2) anaemia requiring 
transfusion, (3) Vitamin B12 or folate deficiency, (4) parathyroid hormone level 
>100pmol/L, (5) urea reduction ratio <65%, (6) presence of systemic haematological 
disease (including antibody-mediated pure red cell aplasia) or known haemoglobinopathy 
and (7) major surgery, infection, acute myocardial infarction or malignancy within the last 
3 months. The study was approved by the institutional Human Research Ethics Committee 
and all patients gave their written informed consent to participate in the study. 
All subjects received iron polymaltose as a parenteral iron-replacement agent according to 
KHA-CARI guidelines. The erythropoetic-stimulating agent (ESA) was Epoetin alfa in nine 
patients and Darbopoetin alfa in one, in the latter the darbopoetin dose was converted to 
an erythropoietin-equivalent value using the recommended conversion factor of 200:1. 
Data on cumulative iron and ESA dose were obtained from review of dialysis unit and 
hospital medical records.  
Biochemical and haematological parameters were collected as standard of care in the 
management of HD subjects, with the only non-standard of care intervention being the 
performance of MR for measurement of liver and cardiac iron concentrations. All scans and 
blood tests were acquired at least 14 days after the most recent iron infusion to avoid 
confounding results. 
 
Liver R2* and cardiac T2* MRI 
MRI using a 1.5 Tesla Siemens Magnetom Vision Plus machine and standardised T2*/R2* 
relaxometry techniques was performed to assess the extent of hepatic and cardiac iron 
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deposition22. The liver iron concentration (LIC) was measured by R2-Ferriscan as previously 
described by our group12,16.  Contiguous ferritin and TSAT levels were obtained to enable 
correlation between blood-based measures of body iron content and MR techniques. 
The reference range for LIC was 3-33mmol/kg dry weight17. A LIC >130mmol/kg has been 
associated with liver injury and a LIC >270mmol/l has been associated with cardiac 
toxicity23. The cardiac T2* reference range was adapted from the work of Wood et al24. 
Cardiac T2* greater than 20ms is not associated with apparent cardiac iron deposition. T2* 
readings of 10-20ms are consistent with some cardiac iron deposition but little immediate 
risk of iron-induced cardiac decompensation. Values less than 10ms represent significantly 
increased risk of iron induced cardiac decompensation.  
 
Statistical analysis 
Statistical analysis was performed with STATA 13.1 (StataCorp. 2013. STATA statistical 
software. College Station, TX: StataCorp LP) using standard parametric and nonparametric 
methods. Correlation coefficients were assessed using Pearsons method. All P-values are 




Ten patients (3 males, 7 females) participated in this study. The median age was 61 years 
(95% confidence interval (CI) 50 - 71), time on HD 2.5 years (95%CI 2.0-5.3), cumulative 
iron dose 4300mg (95%CI 2110-9045) and ESA weekly dose 7625U (95%CI 2623-13126) 
(Table 1).  Median TSAT was 26% (95%CI 19-38) and serum ferritin was 371µg/l (95%CI 175-
1025). None of the patients had TSAT >50%, but 4 patients had serum ferritin >500µg/l. 
 
Liver R2 and cardiac T2* MRI 
Median LIC was 46mmol/kg (95%C 31-76), 8 patients had LICs above the upper limit of the 
reference range (33mmol/kg) and 2 patients had LICs >60mmol/kg. Median cardiac T2*was 
27.4ms (95%C 24.4-32.9) and all patients were within the reference range. There was no 
correlation between LIC and cardiac T2* iron concentration (R2 0.27, p=0.12)  (Figure 1). 
 
Correlations between MRI and other key variables 
There was a significant correlation between LIC and serum ferritin levels (R2 0.63, P<0.01). 
However, there was no significant correlation between LIC and either TSAT (R2 0.004), 
cumulative iron dose (R2 0.03) or time on dialysis (R2 0.09). There was no correlation 
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Our study extends the observations of previous investigators12, 18 by demonstrating that the 
majority (80%) of long-term HD patients receiving iron therapy exhibit significantly 
elevated LICs, but with no increase in cardiac iron concentration. In fact, cardiac T2* 
results for all 10 study patients fell within normal limits, excluding cardiac iron overload in 
our cohort. This is consistent with the findings of Ghoti et al.20, who performed MR 
examination of both liver and heart using MRI T2* studies in 21 HD patients in Israel. The 
lack of statistical significance is likely to be explained by the small sample size in the 
current study thus lacking the power to demonstarte the relationship of iron accumulation 
between two known target organs of iron overload15. Furthermore, only 20% of patients 
exceeded the LIC threshold for iron chelation in other settings23, compared to 60% in our 
previous study12. In the latter the cumulative Fe dose was the strongest determinant of LIC 
and on average it was 25% higher in the previous cohort12. It is therefore possible that 
ESKD patients with evidence of more pronounced liver iron overload may demonstarte 
increase cardiac iron deposition. Thus, a high index of suspicion should be maintained for 
measurement of LIC using noninvasive MR-based methods in patients receiving large 
dosages of parenteral iron/ESA over a protracted period and who exhibit persistent 
hyperferitinaemia as this is the only method that is accurate for diagnosis of tissue iron 
overload in this setting. 
The clinical relevance of the LIC above the threshold for iron chelation23 in dialysis 
patients is uncertain, as none had apparent hepatic decompensation on the basis of blood 
tests or physical examination. None of them had severely elevated LICs >130mmol/kg, a 
level associated with increased risks of liver injury and fibrosis in hemochromatosis25. 
Severely elevated LIC is used as to identify subjects at risk of iron induced cardiomyopathy 
in thalassaemia major and other transfusion dependent disorders24. No study patient 
approached this LIC threshold and this may reflect the much lower levels of iron loading 
incurred during iron and ESA treatment of HD subjects. The estimated average cumulative 
iron dose of a transfusion dependent thalassaemia major patient is 0.4 mg/kg/day26, 27, 
whereas our study patients received a mean 0.055 mg/kg/day. Post-mortem studies of HD 
patients in the 1970s-1980s demonstrated cardiac siderosis7, 28, 29. However, these took 
place at a time when anaemia was routinely treated with blood transfusions, iron 
replacement regimes were less conservative and ESA were not routinely used. It is likely 
that such patients also received substantially larger cumulative iron dosages than would 
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be typical today thus accounting for the discrepancy. As ESA can induce production of 
erythroferrone, a known inhibitor of hepcidin production30, it is also possible that it may 
promote unloading of iron stored in various tissue repositories, including the liver and 
myocardium, potentially reducing the severity of iron loading. 
The poor correlation between LIC and TSAT levels in HD patients confirms previous 
observations by multiple groups12, 23, 31. It has been attributed to highly variable serum iron 
levels and TSAT in the context of intercurrent inflammation together with the effects of 
intemittent iron dosing and normal diurnal variation. Interestingly we identified a 
moderate correlation with serum ferritin (R2 0.63, p<0.01) but not with either dialysis time 
or cumulative iron dose. Whilst at variance with an earlier observation by our group12 it 
demonstrates that ferritin levels may also be unreliable in the population of HD subjects 
as a guide of iron status. A possible explanation resides in differences between the two 
study cohorts as patients in this study received smaller cumulative iron dosages, had lower 
ferritin levels, a shorter HD duration and higher mean CRP. 
We conclude that adherence to current guidelines for ESA/parenteral iron replacement 
can result in LIC’s above the upper limits of the reference range. However, cardiac 
siderosis does not accompany this increase in liver iron concentration. Therefore, these 
data suggest that current dosing of iron in haemodialysis is safe form a cardiac perspective 
with no sign of cardiac iron excess. Serum iron markers are poor predictors of either liver 
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Table 1 Patient demographics and biochemical parameters and MRI iron concentration 
results in 10 chronic maintenance haemodialysis patients. Results are median 
and 95% confidence interval (CI) 
 Median 95% CI 
Age 61 50–71 
BMI (kg/m2) 35.1 30.2-40.4 
Dialysis (years) 2.5 2.0-5.3 
ESA dose (U/week) 7625 2623-13126 
Cumulative Fe (mg) 4300 2110-9045 
Cumulative Fe (mg/kg) 60 17-140 
Monthly Fe dose (mg) 144  92-189 
TSAT (%) 26 19-38 
Ferritin (µg/l) 371 175-1025 
Hb (g/l) 110 103-114 
LIC (mmol/kg) 37 31-76 
Cardiac T2* (ms) 27.4 24.4-32.9 
 
ESA: Erythropoetic stimulating agents, LIC: liver iron concentration,  
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Figure 1 Correlation between iron concentration in the liver, measured by R2*-Ferriscan 
and heart, measured by cardiac T2* MRI. 
